There are currently 118 active clinical trials seeking participants for Head and Neck Cancer research studies. The states with the highest number of trials for Head and Neck Cancer participants are California, Ohio, Pennsylvania and New York.
Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer
Recruiting
Background: Cisplatin is used to treat head and neck cancer. People who take this drug are at risk for hearing loss. Atorvastatin is a drug used to treat high cholesterol. It might reduce the risk of cisplatin-induced hearing loss. Objective: To find out if atorvastatin reduces hearing loss in people treated with cisplatin and radiation. Eligibility: People ages 18 and older with squamous cell carcinoma of the head and neck who will undergo treatment with cisplatin-based chemotherapy and ra... Read More
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
05/20/2024
Locations: Winship Cancer Institute at Emory University, Atlanta, Georgia +3 locations
Conditions: Hearing Loss, Head and Neck Cancer
Study of Proton Versus Photon Beam Radiotherapy in the Treatment of Head and Neck Cancer
Recruiting
Compared to IMRT, PBRT is thought to give less radiation exposure to the surrounding healthy tissues. It is possible that side effect rates with PBRT will be lower or the same compared to IMRT, but this has not been well studied to date. Although both of these radiation therapies have been used in the past to treat head and neck cancer, this research study will compare the effects of these two different radiation treatment modalities with each other to see whether PBRT is better, the same or wor... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/17/2024
Locations: Baptist Alliance MCI, Miami, Florida +8 locations
Conditions: Head and Neck Cancer
Implementation and Effectiveness Trial of HN-STAR
Recruiting
People who have been treated for head and neck cancer (HNC survivors) can experience serious consequences from their cancer and its treatment, ongoing risks of new cancers, and other unrelated illnesses. These concerns pose challenges to the provision of comprehensive care to HNC survivors. We created HN-STAR to facilitate and tailor the ongoing care of HNC survivors. Survivors use HN-STAR on a computer or tablet to answer questions about symptoms and health concerns before a routine visit with... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/16/2024
Locations: Kingman Regional Medical Center, Kingman, Arizona +40 locations
Conditions: Head and Neck Cancer
Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)
Recruiting
The purpose of this study is to demonstrate the superior efficacy of Xevinapant (Debio 1143) versus placebo when added to radiotherapy in the treatment of high-risk participants with resected locally advanced squamous cell carcinoma of the head and neck (LA SCCHN) who are ineligible to receive cisplatin-based chemoradiation concurrently. Study details include: Study duration: Participants will be followed until the last on-study participant reaches his/her 60-month post-randomization visit, a de... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/16/2024
Locations: University of Alabama at Birmingham - Dept of Radiation Oncology, Birmingham, Alabama +205 locations
Conditions: Head and Neck Cancer
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Recruiting
This is a proof-of-concept study designed to investigate HER3-DXd monotherapy in locally advanced or metastatic solid tumors. The study is enrolling cohorts of participants with melanoma [cutaneous/acral], squamous cell carcinomas of the head and neck (SCCHN), and HER2-negative gastric cancer, ovarian carcinoma, cervical cancer, endometrial cancer, bladder cancer, esophageal carcinoma, pancreatic carcinoma, and prostate cancer.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/15/2024
Locations: Washington University, School of Medicine, Saint Louis, Missouri +2 locations
Conditions: Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Pancreatic Carcinoma, Prostate Cancer
PromotinG Lung Cancer screenIng Awareness and Implementation in Hispanics/Latinx Head and Neck canceR Survivors
Recruiting
The purpose of this study is to assess the awareness of eligibility of lung cancer screening in Hispanic/LatinX Head and Neck Cancer (HNC) survivors using a survey questionnaire; and to understand the barriers to screening using qualitative interviews.
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
05/15/2024
Locations: University of Miami, Miami, Florida
Conditions: Head and Neck Cancer
Tumescence in HNC Skin Graft Reconstruction
Recruiting
Our primary objective is to determine if the use of tumescence has a meaningful effect on STSG uptake at the recipient site. This is an important outcome because poor graft uptake results in the need for prolonged local wound care, additional clinic visits for patients and increased risk of infection. A prospective, randomized comparison of the tumescence to our current standard of care will allow us to definitively evaluate any benefits to this technique. Tumescence is commonly used in the tre... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/14/2024
Locations: UC Davis Health, Sacramento, California
Conditions: Head and Neck Cancer, Surgery--Complications, Graft Failure
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Recruiting
Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal antibody as monotherapy or in combination with cemiplimab in patients with advanced solid tumors.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/13/2024
Locations: Icahn School of Medicine at Mt. Sinai, New York, New York +4 locations
Conditions: Solid Tumor, Adult, Advanced Solid Tumor, Head and Neck Cancer, Breast Cancer, Colon Cancer, Pancreatic Cancer, Gastric Cancer, Esophageal Cancer, Prostate Cancer, Uterine Cancer, Cervix Cancer, Ovarian Cancer, Kidney Cancer, Bladder Cancer, Thyroid Cancer, Melanoma, Sarcoma, Advanced Cancer, Metastatic Cancer, Refractory Cancer, Non Small Cell Lung Cancer
Phase 1b Safety Study of Xevinapant, Weekly Cisplatin, and RT in Participants With Unresected LA SCCHN (HyperlynX)
Recruiting
The purpose of this study is to evaluate the tolerability and safety of Xevinapant when added to weekly cisplatin-based concurrent chemoradiotherapy (CRT) in the treatment of participants with unresectable locally advanced squamous cell carcinoma of the head and neck, suitable for definitive chemoradiotherapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/10/2024
Locations: Mount Sinai Comprehensive Cancer Center, Miami Beach, Florida +22 locations
Conditions: Head and Neck Cancer
"QUAD SHOT" Radiotherapy With Pembrolizumab in Patients With Recurrent Head & Neck Cancer
Recruiting
The purpose of this study is to test the safety of palliative "QUAD SHOT" radiotherapy combined with pembrolizumab and evaluate the effects of the combination treatment patients with recurrent cancer of head and neck.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/09/2024
Locations: Stephenson Cancer Center, Oklahoma City, Oklahoma
Conditions: Head and Neck Cancer
A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors
Recruiting
TScan Therapeutics is developing cellular therapies across multiple solid tumors in which autologous participant-derived T cells are engineered to express a T cell receptor that recognizes cancer-associated antigens presented on specific Human Leukocyte Antigen (HLA) molecules. This is a multi-center, non-randomized, multi-arm, open-label, basket study evaluating the safety and preliminary efficacy of single and repeat dose regimens of TCR'Ts as monotherapies and as T-Plex combinations after ly... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/09/2024
Locations: HonorHealth Research and Innovation Institute, Scottsdale, Arizona +13 locations
Conditions: Head and Neck Cancer, Cervical Cancer, Non-small Cell Carcinoma, Melanoma, Ovarian Cancer, Anogenital Cancers, HPV - Anogenital Human Papilloma Virus Infection, HPV-Related Cervical Carcinoma, HPV-Related Carcinoma, HPV-Related Squamous Cell Carcinoma, HPV-Related Malignancy, HPV-Related Adenocarcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Related Adenosquamous Carcinoma, HPV-Associated Vaginal Adenocarcinoma, HPV-Related Endocervical Adenocarcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Verrucous Carcinoma, HPV-Related Penile Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma, HPV Positive Rectal Squamous Cell Carcinoma
A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)
Recruiting
This is a non-randomized, open-label, single-center, safety and imaging feasibility study of Pegsitacianine, an intraoperative fluorescence imaging agent.
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
05/08/2024
Locations: University of Texas Southwestern Medical Center, Dallas, Texas
Conditions: Head and Neck Cancer, Unknown Primary Cancer, Head and Neck Squamous Cell Carcinoma